This year’s theme, “Free to Be Proud,” comes amid increasing attacks on the LGBTQ+ community across the nation — including in ...
Individual hospitals all over the U.S. have responded to the president's attacks on transgender healthcare by deciding to ...
Morning Overview on MSN
A year of added prostate-cancer therapy cut the odds the disease spreads, a major trial found
Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...
Clinical data reveals male factors contribute to half of all infertility cases, shifting the focus toward earlier ...
The US is in the middle of an estrogen patch shortage, with menopausal women struggling to get ahold of hormone therapy to ...
The "TikTok Medical Group" has stirred the viral waters around biohacking male infertility. GLP-1 receptor agonists are ...
Crinetics Pharmaceuticals stock is a 'Buy' rating due to EU approval and strong initial U.S. uptake of Palsonify for ...
KyneRx announces the nationwide launch of its telehealth platform, providing convenient access to personalized hormone ...
Compounded drugs sold for cash prices don’t generate billing records that would allow regulators to track basic information, ...
Marius Pharmaceuticals has backed a move by the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) to update prescribing information for testosterone ...
The Department of Health and Human Services (HHS) announced plans on June 18 to update label information for testosterone ...
The U.S. Food and Drug Administration (FDA) is asking drugmakers to update the prescribing information on testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results